September 25, 2017
4 min read
Save

Maternal iodine therapy appears safe for thyroid function in breast-feeding offspring

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Inorganic iodine therapy administered to mothers with Graves’ disease did not affect thyroid function in most infants, despite high levels of iodine exposure measured via breast milk, according to a study conducted in Japan.

Perspective from

“In daily clinical practice, inorganic iodine therapy may be administered to pregnant and lactating women with Graves’ disease for whom adverse reactions preclude the use of antithyroid drugs,” Katsuhiko Hamada, MD, PhD, of the Tajiri Thyroid Clinic in Kumamoto, Japan, and colleagues wrote. “However, this inorganic iodine is transferred to fetuses via the placenta and infants via breast milk. Therefore, it is important to know the effects of this type of therapy on fetal and infant thyroid function.”

Hamada and colleagues analyzed data from 26 infants of 23 lactating mothers with Graves’ disease treated with potassium iodide for postpartum thyrotoxicosis between September 2012 and August 2015 (median age, 3 months; 14 boys; median potassium iodide dose, 50 mg per day). Researchers collected blood samples from infants using a filter paper procedure, measuring free thyroxine and thyroid-stimulating hormone, as well as breast milk and infant urine iodine concentrations measured on the same day. Subclinical hypothyroidism was defined as TSH level at least 10 µIU/mL in infants aged 6 months or younger, or at least 5 µIU/mL in infants aged 6 to 12 months.

Within the cohort, 19 infants were exclusively breast-fed, and seven infants received mixed feedings; TSH levels and iodine concentrations did not differ between groups.

Researchers detected high median iodine concentrations in breast milk (median, 15,050 µg/L) and in infant urine (median, 15,650 µg/L), and potassium iodide doses correlated with iodine concentrations in breast milk and urine (P < .001 for both). All but one infant had normal thyroid function; median infant TSH level was 2.1 µIU/mL. One infant, aged 5 months, presented with subclinical hypothyroidism that resolved 2 months after maternal potassium iodide discontinuation.

“We note the scarcity of available data regarding inorganic iodine therapy for lactating mothers with Graves’ disease, and suggest that therapeutic indications should be considered carefully,” the researchers wrote. “However, inorganic iodine therapy appears to be a potentially useful alternative for mothers with Graves’ disease with adverse reactions to antithyroid drugs who are contraindicated for iodine-131 therapy because they wish to continue breast-feeding and do not wish to undergo surgery.”

The researchers noted that the Japanese diet includes high daily levels of iodine ingested via seaweed, and that infants living in regions characterized by low iodine intakes and iodine deficiency might be more strongly affected by iodine overload. – by Regina Schaffer

Disclosures: The authors report no relevant financial disclosures.